VRAX
NASDAQVirax Biolabs Group Limited
Price$3.73+0.52 (+16.27%)
2026-04-212026-07-24
News · 26 weeks29+233%
2026-02-012026-07-26
Mix1790d
- Other9(53%)
- SEC Filings7(41%)
- Offering1(6%)
Latest news
25 items- SECSEC Form F-3 filed by Virax Biolabs Group LimitedF-3 - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs' CEO James Foster Provides Shareholder Update Following Fiscal 2026 Annual Report and Fosun Diagnostics Commercial Supply AgreementFiscal 2026 Annual Report, filed July 2, 2026, reflects cash of $6.4 million, total assets of $8.3 million and shareholders' equity attributable to ordinary shareholders of $7.3 millionFosun Diagnostics agreement, announced July 9, 2026, supports commercial execution for ImmuneSelect across six Southeast Asian marketsPreferred investment option exercise, completed July 10, 2026, generated approximately $3.3 million in gross proceeds, further strengthening the Company's liquidity position and balance sheetNasdaq confirmed on July 13, 2026, that the Company regained compliance with the minimum bid price requirementLONDON, July 16, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Group Limited Announces Closing of Exercise of Preferred Investment Options for $3.3 Million Gross ProceedsLONDON, July 10, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX) today closed its previously announced exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share. The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (Nos. 333-292241 and 333-275893). The gross p
- PRThese Companies Just Dropped Major Growth CatalystsDENVER, July 10, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) -- A wave of corporate announcements, from international distribution agreements and manufacturing leadership appointments to expanding government contracts and enterprise AI initiatives, several companies confirm strengthening revenue opportunities and long-term execution. Virax Expands into Southeast Asia Through Exclusive Fosun Diagnostics Partnership Virax Biolabs (NASDAQ:VRAX) announced a significant commercial milestone by signing an exclusive multi-country commercial supply agreement with Fosun Diagnostics covering Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia. The agreement allows immediate
- PRVirax Biolabs Group Limited Announces Exercise of Preferred Investment Options for $3.3 Million Gross ProceedsLONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited ("Virax" or the "Company") (NASDAQ:VRAX) announced today that it has entered into a definitive agreement for the immediate exercise of certain outstanding preferred investment options to purchase up to an aggregate of 548,000 ordinary shares of the Company, par value $0.025 (the "Ordinary Shares") originally issued in October 2023 (as amended in December 2025) and in December 2025 having an original exercise price of $10.00 per share, at a reduced exercise price of $6.00 per share. The resale of the Ordinary Shares issuable upon exercise of the warrants are registered pursuant to effective registration statements on Form F-3 (
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Signs Multi-Country Commercial Supply Agreement with Fosun DiagnosticsLONDON, July 9, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial supply agreement with Fosun Diagnostics for the Company's ImmuneSelect research-use immune profiling product line. The agreement covers six Southeast Asian markets, including Thailand, Vietnam, Indonesia, the Philippines, Singapore and Malaysia, and establishes a framework for immediate product supply under purchase orders, supporting near-term potential revenue opportunities and regional commercial expansion.
- SECSEC Form 20-F filed by Virax Biolabs Group Limited20-F - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Group Limited Announces 1-for-25 Share ConsolidationLONDON, June 24, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that the board of directors of the Company approved a share consolidation of the Company's authorized, issued and outstanding ordinary shares of US$0.001 par value each at a ratio of 1-for-25 effective 26 June 2026 (the "Share Consolidation"). The shareholders approved the Share Consolidation at the adjourned extraordinary general meeting of the shareholders held on Friday, June 12, 2026, at 2.00 p.m. local time at BioCity Glasgow, Bo'Ness Road, Newhouse, Lanarkshire. At the opening of trading on June 26, 2026, the Company's ordinary shares will begin trading on a post-S
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs Reports Positive Early Clinical Data for ViraxImmune™ in Long COVID and Related Post-Acute Infection SyndromesLONDON, May 26, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today reported positive early pilot performance data for ViraxImmune™, its blood-based test in development for Long COVID, myalgic encephalomyelitis/chronic fatigue syndrome ("ME/CFS") and related post-acute infection syndromes ("PAIS"). In the pilot dataset, ViraxImmune™ demonstrated measurable separation between PAIS patients and healthy controls, achieving 88% specificity and 92% positive predictive value ("PPV") — early performance metrics that Virax believes support continued development and advancement into larger clinical validation.
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Virax Biolabs Group LimitedSCHEDULE 13G/A - Virax Biolabs Group Ltd (0001885827) (Subject)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- PRVirax Biolabs' CEO James Foster Outlines Strategic Priorities and Near-Term Milestones in Letter to ShareholdersVirax Biolabs is advancing a focused strategy centered on ViraxImmune™ and a U.S. market-entry pathway, which management believes is not reflected in the Company's current public valuation despite its balance sheet strength, debt-free position, recent financing and operational progress.LONDON, April 14, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on immunology research and diagnostics, today published a shareholder letter from Chief Executive Officer James Foster and released an updated investor presentation. Together, these materials outline Virax's current strategic and commercial framework and the m
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- INSIDERSEC Form 3 filed by new insider Haight Nelson M3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- PRVirax Biolabs Achieves ISO Certifications, Laying Foundation for Regulated IVD Development and U.S. Clinical ValidationLONDON, March 31, 2026 /PRNewswire/ -- Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certification for its quality management system. The certifications were issued by LRQA, with an issue date of 18 February 2026 and an expiry date of 17 February 2029. Highlights:Virax believes the strengthened quality framework supports its post-acute infection syndromes ("PAIS") strategy by strengthening readiness for regulated in vitro diagnostic (
- INSIDERSEC Form 3 filed by new insider Mccracken Nigel William3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
- SECSEC Form 6-K filed by Virax Biolabs Group Limited6-K - Virax Biolabs Group Ltd (0001885827) (Filer)
- INSIDERSEC Form 3 filed by new insider Foster James Alexander Cunliffe3 - Virax Biolabs Group Ltd (0001885827) (Issuer)
VRAX FAQ
7 questionsWhat does Virax Biolabs Group Limited do?
Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company offers rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name. It also distributes nebulizing machines and smart wearable devices that...Where does VRAX stock trade?
Virax Biolabs Group Limited (VRAX) is listed on NASDAQ.What sector and industry is VRAX in?
Virax Biolabs Group Limited operates in the Health Care sector, Biotechnology: In Vitro & In Vivo Diagnostic Substances industry.When did Virax Biolabs Group Limited go public?
Virax Biolabs Group Limited (VRAX) completed its IPO in 2022.What are analysts saying about VRAX?
Virax Biolabs Group Limited has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Buy with a $300.00 price target on 2025-03-31. Recent price targets cluster around $300.00.What companies are similar to VRAX?
Notable peers in the same industry include IDXX (IDEXX Laboratories Inc.), LNTH (Lantheus Holdings Inc.), ORKA (Oruka Therapeutics Inc.), OCDX (Ortho Clinical Diagnostics Holdings plc), CLDX (Celldex Therapeutics Inc.). Compare VRAX side-by-side with any of them on Quantisnow.How can I track VRAX on Quantisnow?
Quantisnow aggregates Virax Biolabs Group Limited's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow VRAX to receive live email and push alerts on every new disclosure.